Rezolute, Inc. (NASDAQ:RZLT) Shares Bought by XTX Topco Ltd

XTX Topco Ltd grew its holdings in Rezolute, Inc. (NASDAQ:RZLT) by 67.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 56,375 shares of the company’s stock after buying an additional 22,704 shares during the quarter. XTX Topco Ltd owned about 0.10% of Rezolute worth $273,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Jeppson Wealth Management LLC acquired a new stake in Rezolute in the second quarter valued at $45,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Rezolute in the 3rd quarter valued at about $65,000. Cubist Systematic Strategies LLC lifted its stake in shares of Rezolute by 366.0% in the second quarter. Cubist Systematic Strategies LLC now owns 54,237 shares of the company’s stock valued at $233,000 after purchasing an additional 42,597 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in Rezolute during the third quarter worth about $239,000. Finally, Dimensional Fund Advisors LP acquired a new position in Rezolute during the second quarter worth about $255,000. 82.97% of the stock is currently owned by hedge funds and other institutional investors.

Rezolute Trading Down 8.1 %

Shares of RZLT stock opened at $4.08 on Thursday. The company has a market capitalization of $236.41 million, a price-to-earnings ratio of -3.21 and a beta of 1.01. The firm has a 50-day moving average price of $5.14 and a 200 day moving average price of $4.78. Rezolute, Inc. has a twelve month low of $0.86 and a twelve month high of $6.19.

Rezolute (NASDAQ:RZLT) last announced its quarterly earnings data on Thursday, September 19th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.14). As a group, research analysts predict that Rezolute, Inc. will post -0.99 earnings per share for the current year.

Insider Buying and Selling at Rezolute

In other Rezolute news, CFO Daron Evans purchased 9,000 shares of the stock in a transaction on Thursday, December 12th. The stock was bought at an average price of $4.60 per share, for a total transaction of $41,400.00. Following the acquisition, the chief financial officer now directly owns 140,900 shares of the company’s stock, valued at $648,140. This represents a 6.82 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. In the last three months, insiders acquired 23,259 shares of company stock worth $104,317. Insiders own 18.39% of the company’s stock.

Analyst Ratings Changes

RZLT has been the topic of several research analyst reports. BTIG Research boosted their price target on Rezolute from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday, September 10th. JMP Securities reiterated a “market outperform” rating and set a $7.00 target price on shares of Rezolute in a research report on Friday, September 20th. HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of Rezolute in a research report on Friday, November 8th. Guggenheim began coverage on shares of Rezolute in a research report on Tuesday, August 27th. They issued a “buy” rating and a $11.00 price objective on the stock. Finally, Wedbush restated an “outperform” rating and set a $112.00 target price on shares of Rezolute in a report on Monday, November 4th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $24.13.

Rezolute Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.